UBS has initiated coverage on IDEXX Laboratories Inc (IDXX) with a Neutral rating as of September 30, 2025. The current share price stands at $719.36. This marks UBS's first assessment of the company's investment potential, reflecting their analysis of IDEXX's business, industry dynamics, and growth prospects.
IDEXX Laboratories, headquartered in Westbrook, Maine, specializes in the development, manufacture, and distribution of products and services for veterinary and livestock markets, as well as water testing. The company operates in the Health Care industry and has a market capitalization of $56.6 billion. IDEXX reported a trailing twelve-month price-to-earnings ratio of 55.13 and earnings per share of 12.61.
Upcoming earnings are scheduled for August 3, 2026, with an estimated EPS of $3.95 and revenue of $1.2 billion. Analyst consensus indicates a Buy rating, with 7 Strong Buy, 8 Buy, and 7 Hold ratings among 22 analysts.
This update provides insight into the evolving landscape of analyst ratings, which can change as new information becomes available. Investors are encouraged to consider a range of factors when making investment decisions, including company fundamentals and market conditions.